$RXRX

RECURSION PHARMACEUTICALS, INC.

Recursion Pharmaceuticals, commonly known as Recursion, is a clinical-stage TechBio company headquartered in Salt Lake City, Utah. It develops medicines for patients by applying its Recursion Operating System, an AI-native platform that combines biological data, machine learning, automated laboratory experiments, small-molecule design and clinical development. The platform supports drug discovery from biological research through clinical trials. Recursion advances its own drug programs, focused on oncology and rare diseases, and works with pharmaceutical partners on discovery and development programs across areas including neuroscience, immunology and oncology. Its pipeline includes clinical and preclinical programs, with products such as REC-4881 for familial adenomatous polyposis and REC-617 for advanced solid tumors. Recursion makes money through partner payments, including upfront and milestone payments, and is eligible for royalties on partnered programs.

5
1
1
—
$155K
Borgeson Blake
100%
See all $RXRX insider activity →

Recursion Pharmaceuticals Earnings Call Signals Clinical Momentum

Recursion Pharmaceuticals (RXRX) reported Q3 earnings, highlighting positive early data for REC-4881 and REC-1245, partnerships, and $535M in partner cash inflows. REC-4881 showed polyp burden reduction in FAP patients, while REC-1245 demonstrated tumor responses. The company secured $200M in financing, extending runway into 2029. Risks include safety events and regulatory hurdles.

RXRX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 7 news stories mentioning RXRX (RECURSION PHARMACEUTICALS, INC.). Coverage has skewed bullish: 5 bullish, 1 neutral, and 1 bearish.

Recent RXRX coverage spans financial news and earnings.

In the last 30 days, RXRX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($155K). The most active reporter was Borgeson Blake with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving RXRX

AlphAI scores every news story that mentions RXRX with an AI model for sentiment and relevance, and aggregates insider trades from RECURSION PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RXRX

Score

Recursion Pharmaceuticals Earnings Call Signals Clinical Momentum

Recursion Pharmaceuticals (RXRX) reported Q3 earnings, highlighting positive early data for REC-4881 and REC-1245, partnerships, and $535M in partner cash inflows. REC-4881 showed polyp burden reduction in FAP patients, while REC-1245 demonstrated tumor responses. The company secured $200M in financing, extending runway into 2029. Risks include safety events and regulatory hurdles.

Recursion Pharmaceuticals Inc (RXRX) Q3 2026 Earnings Call Highlights: Durable FAP Data

Recursion Pharmaceuticals (RXRX) discussed Q3 2026 earnings, highlighting durable FAP data for REC-481, showing 92% of patients maintained polyp burden reduction after 12 weeks off treatment. CEO Najat emphasized AI-driven differentiation and data-driven capital allocation, with $535M in cash inflows from partnerships. REC-1245 showed early promise in endometrial cancer. The company guided to lower operating expenses in 2027 and has runway into 2029.

$RXRXMedAI 8/10

Recursion Pharma Q3 Net Loss Narrows, Reports Positive REC-4881 Data; Advances Pipeline

Recursion Pharmaceuticals (RXRX) reported Q3 2026 net loss narrowed to $119.0M from $162.3M YoY. Revenue rose to $18.55M, driven by a $10M Sanofi milestone payment. REC-4881 showed positive FAP trial results, with significant polyp burden reductions. REC-1245 demonstrated preliminary efficacy in cancers. RXRX expects cash to last into 2029. Stock is down 4.96% to $3.83.

$RXRXMedAI 8/10

Two patients each went from over 90 large polyps to one

Recursion (RXRX) reported positive Phase 2 data from the TUPELO trial of REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). After 12 weeks, patients saw a 47% median reduction in polyp burden, with 85% remaining below baseline 12 weeks post-treatment. Two patients reduced their larger polyp counts from over 90 to one. No new safety signals were observed. The company plans to initiate a registrational trial in 2027, pending FDA discussions.

RXRX Stock Jumps As Sanofi Deal And Trial Data Ignite AI Drug Story

Recursion Pharmaceuticals (RXRX) stock rose 7.04% on October 28, 2026, driven by positive clinical trial data, a Sanofi deal, and a $200M equity raise. The company reported encouraging results for REC-4881 and REC-1245, while Sanofi's option exercise brought total payments to $144M. RXRX has a market cap of $74.3M, a price-to-sales ratio of 43, and significant cash reserves.

$RXRXHighAI 8/10

RXRX Stock Pops As Sanofi Deal, ARK Buying Fuel AI Biotech Story

Recursion Pharmaceuticals Inc. (RXRX) stock rose 3.85% on AI-driven drug discovery progress and institutional buying. The company reported positive Phase 1b/2 data for REC-4881 and REC-1245, and Sanofi exercised an option on an inflammatory candidate, triggering a $10M milestone. RXRX raised $200M in a follow-on offering, and ARK Investment Management has been accumulating shares. The company has no near-term profits but has a strong cash position and strategic partnerships.

Related tickers